Skip to main content

CORRECTION article

Front. Immunol., 25 November 2022
Sec. Cancer Immunity and Immunotherapy
Volume 13 - 2022 | https://doi.org/10.3389/fimmu.2022.1099835

Corrigendum: DCBLD1 Overexpression is associated with a poor prognosis in head and neck squamous cell carcinoma

This article is a correction to:

  1. DCBLD1 Overexpression Is Associated With a Poor Prognosis in Head and Neck Squamous Cell Carcinoma

    1. Read original article
Ling-ling Fu,&#x;Ling-ling Fu1,2†Ming Yan,&#x;Ming Yan1,2†Min-Xian MaMin-Xian Ma1Yi LuoYi Luo1Min ShaoMin Shao1Martin GosauMartin Gosau2Reinhard E. FriedrichReinhard E. Friedrich2Tobias VollkommerTobias Vollkommer2Hong-chao Feng*Hong-chao Feng1*Ralf Smeets,Ralf Smeets2,3
  • 1Department of Oral and Maxillofacial Surgery, Guiyang Hospital of Stomatology, Guiyang, China
  • 2Department of Oral and Maxillofacial Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
  • 3Department of Oral and Maxillofacial Surgery, Division of Regenerative Orofacial Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

A Corrigendum on:
DCBLD1 Overexpression is associated with a poor prognosis in head and neck squamous cell carcinoma

by Fu L-l, Yan M, Ma M-X, Luo Y, Shao M, Gosau M, Friedrich RE, Vollkommer T, Feng H-c and Smeets R (2022) Front. Immunol. 13:939344. doi: 10.3389/fimmu.2022.939344

In the published article, there was an error in affiliations 1 and 2. Instead of “1Department of Oral and Maxillofacial Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, 2Department of Oral and Maxillofacial Surgery, Guiyang Hospital of Stomatology, Guiyang, China, “, it should be “1Department of Oral and Maxillofacial Surgery, Guiyang Hospital of Stomatology, Guiyang, China, 2Department of Oral and Maxillofacial Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany,”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is notguaranteed or endorsed by the publisher.

Keywords: DCBLD1, biomarker, immune infiltrates, prognosis, head and neck squamous cell carcinoma

Citation: Fu L-l, Yan M, Ma M-X, Luo Y, Shao M, Gosau M, Friedrich RE, Vollkommer T, Feng H-c and Smeets R (2022) Corrigendum: DCBLD1 Overexpression is associated with a poor prognosis in head and neck squamous cell carcinoma. Front. Immunol. 13:1099835. doi: 10.3389/fimmu.2022.1099835

Received: 16 November 2022; Accepted: 17 November 2022;
Published: 25 November 2022.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2022 Fu, Yan, Ma, Luo, Shao, Gosau, Friedrich, Vollkommer, Feng and Smeets. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Hong-chao Feng, aGNmZW5nQGd6dS5lZHUuY24=

†These authors have contributed equally to this work

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.